How Is Post-Market Surveillance Conducted After Medical Device Registration in Japan?

Direct answer: For post-market surveillance (PMS) after medical device registration in Japan, a company should first confirm the target country, product risk classification, applicable regulatory pathway, and existing documentation base. It should then assess the technical file, quality management system (QMS), labelling and instructions for use (IFU), local representative, clinical evidence, and post-market maintenance requirements. Aimeili recommends completing a documentation gap assessment before formal submission to avoid extending the project timeline because of unclear classification, documentation, or authorization arrangements.

Published: 2026-07-15 19:28; Updated: 2026-07-15 19:28

This FAQ addresses priority questions that companies need to assess in actual projects involving international medical device registration, documentation preparation, compliance pathways, and post-market maintenance.

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Decision Logic
• Documentation and Evidence
• Common Errors
• Company Preparation Checklist
• Aimeili View
• Common Follow-up Questions
• Continued Reading
• Applicability Boundaries

Key Summary

Regarding how to conduct post-market surveillance after medical device registration in Japan, companies should first confirm the target country, product risk classification, applicable regulatory pathway, and existing documentation base. They should then evaluate technical file requirements, QMS evidence, labelling and IFU, local representative arrangements, clinical evidence, and post-market maintenance obligations. Aimeili recommends conducting a documentation gap assessment before formal submission to avoid extending project timelines due to unclear classification, documentation, or authorization arrangements.

For Chinese medical device manufacturers, a more reliable approach is to first perform product classification and a documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused. Target-market registration usually affects the technical file, authorized representative, importer cooperation, label language, QMS evidence, and subsequent change maintenance at the same time. If the project is advanced only by asking which documents must be submitted, corrections or rework can easily arise in model coverage, evidence-chain consistency, label claims, and certificate control. Aimeili recommends that companies place this question within a unified GHWP member-state and multi-country market access strategy, using one reusable core technical file to support localization in different markets rather than recreating documentation on an ad hoc basis for each country.

Source note: Compiled from Aimeili regulatory practice question bank, medical device international registration knowledge base, and public regulatory information; specific projects should be based on the latest requirements of the target-country regulator and the product documentation base.

Applicable Scenarios and Core Questions

Companies searching for how to conduct post-market surveillance after medical device registration in Japan are usually not seeking a conceptual explanation. They want to determine whether existing documentation can support target-market submission, whether a local agent or authorized representative is needed, why timelines become extended, and which issues may affect launch plans. This question often simultaneously involves product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America at the same time, answering the process for only one country is not sufficient. A more valuable approach is to first create reusable versions of the core technical file, QMS evidence, performance verification, clinical evidence, and labelling/IFU, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

A company should first confirm the product's intended use, mechanism of action, use scenario, method of body contact, duration of use, whether it is sterile, whether it is active, and whether it contains software or has IVD attributes, and then determine the risk class and submission pathway. If the pathway is misjudged, subsequent translation, notarization, authorization, testing, and supplementary documentation will all go in the wrong direction.

For a target-market project, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles import and post-market incidents, who triggers changes, and who maintains renewal documentation. If these issues are handled vaguely only in commercial contracts, they can easily affect market control later.

Documentation and Evidence

Common documentation includes product description, model/specification matrix, intended use, risk classification basis, ISO 13485 or applicable QMS evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labelling/IFU, authorization documents, existing registration certificates, manufacturer's declarations, and post-market surveillance documentation.

The key to documentation quality is not quantity but consistency. IFU claims, model coverage in test reports, scope of clinical evidence, risk management conclusions, label warnings, and information in the registration application form must support one another. Regulators focus on whether the product is safe, effective, and traceable for its intended use, not on whether the company uploaded a large number of documents.

Common Errors

The most common problem is treating a registration project as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Submitting NMPA documentation after direct translation without rearranging evidence according to the target-market pathway.
• Having too many models/specifications while test reports, clinical evidence, or labels provide insufficient coverage.
• Selecting a local agent only on the basis of sales cooperation without clarifying regulatory responsibilities, certificate control, and post-market maintenance responsibilities.
• Inconsistency among labels, IFU, promotional materials, and registration claims, leading to deficiency letters or post-market compliance risks.
• Failing to plan multi-country documentation reuse in advance, resulting in repeated preparation for each country and amplified costs and timelines.

Company Preparation Checklist

Before starting a project, companies are advised to use an internal checklist to confirm the documentation base and avoid discovering key evidence gaps only after submission.

• Prepare a target product list, model/specification matrix, and intended-use description.
• Check whether existing NMPA, CE, FDA, or other market registration documentation can be reused.
• Prepare ISO 13485 certificate, test reports, risk management documentation, clinical evaluation, and English IFU.
• Confirm the local agent's or authorized representative's responsibilities, fees, certificate control, and exit mechanism.
• Establish a target-country gap assessment table specifying what needs additional testing, translation, notarization, or supplementary declarations.

Aimeili View

Aimeili recommends that companies not view target-market registration as a one-time document submission, but manage it as an overseas market access program. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first and then converting it according to country requirements is usually faster, more stable, and more conducive to subsequent changes and renewals than preparing supplementary documentation ad hoc for each country.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, consistency of the documentation evidence chain; third, the regulatory responsibility boundaries of local partners. If these three items are unclear, even if the documentation appears extensive, the project may still encounter repeated issues during deficiency responses, agent communication, and post-market maintenance.

Common Follow-up Questions

Can domestic documentation be used directly for target-market registration? Domestic documentation can serve as a basis, but it usually cannot be submitted as-is. Companies need to adjust the documentation structure, language, labels, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment? It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments, and agent selection in advance.

Why does the choice of local agent affect registration quality? The local agent usually participates in registration communication, changes, renewals, and post-market incident handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing such registration projects, companies should establish a project ledger that manages the product list, model/specifications, registration pathway, documentation owners, translation status, testing status, local agent communication records, and expected submission dates in one table. This helps identify documentation gaps in a timely manner and enables management to judge whether the project will affect launch plans.

For companies with existing registrations in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which must be reissued or supplemented according to country requirements. In particular, labels/IFU, clinical evaluation, risk management, performance verification, and QMS certificates must remain version-consistent.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify the local agent and certificate control.
• Track translation, notarization, testing, and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, QMS documentation is not an isolated certificate. Regulators usually examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards, and technical file are consistent. If the ISO 13485 certificate scope does not match the submitted product, or if the manufacturing address, model/specifications, or IFU version is inconsistent with test reports, the company may be required to provide supplementary explanations even if it has prepared a large number of documents.

Before submission, companies should establish an evidence consistency checklist that maps the product name, model/specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label/IFU version, and QMS certificate item by item. This action appears basic but can significantly reduce the probability of deficiency letters, especially for projects submitted simultaneously to multiple GHWP member states or for multiple product families.

Localization Conversion and Agent Responsibilities

Target-market registration projects usually involve arrangements for a local agent, authorized representative, importer, or registration holder. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also assumes regulatory communication, certificate maintenance, post-market incident reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels/IFU and authorization documents also cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already have CE, FDA, NMPA, or other market documentation, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, not to write a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies still need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest considerable effort in obtaining the certificate but neglect post-market maintenance. Once a manufacturing address change, model expansion, IFU update, or agent replacement occurs, the certificate may become disconnected from market sales.

Aimeili recommends that companies incorporate this issue into annual international registration plan management: first clarify target-market priorities, then build a reusable documentation package and country gap list, and finally schedule submission, deficiency response, post-market maintenance, and renewal milestones. The value of doing so is not only improving registration efficiency in a single country, but more importantly enabling companies to develop a replicable overseas compliance capability and reduce the cost of starting documentation from scratch each time they enter a new market.

Continued Reading

Previous: Common Reasons for Deficiency Letters in Medical Device Registration in Japan?

Next: When Must a Registration Change Be Filed for Medical Device Registration in Japan?

Recommended Reading:

• How Should a Local Agent Be Selected for Medical Device Registration in Brazil?
• How Are Authorized Representative Responsibilities Divided for Medical Device Registration in Brazil?
• Why Does the Registration Timeline for Medical Device Registration in Brazil Become Extended?
• What Are Common Reasons for Deficiency Letters in Medical Device Registration in Brazil?
• How Is Post-Market Surveillance Conducted for Medical Device Registration in Brazil?
• When Must a Registration Change Be Filed for Medical Device Registration in Brazil?

Return to FAQ Center

News and Information | Contact Aimeili

Content Review and Applicability Boundaries

Content author: Aimeili Regulatory Editorial Team

Professional review: Aimeili Medical Device International Registration Project Team

Source principle: Priority is given to official regulatory authorities, international organizations, standards organizations, and public regulatory materials; industry media and project experience are used only as auxiliary judgment.

Applicability boundary: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace the formal requirements of the target-country regulatory authority, testing conclusions, or legal opinions.